RINVOQ® (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
Active psoriatic arthritis when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated
